https://www.selleckchem.com/products/mf-438.html
Head and neck cancer represents a variety of tumors involving different organs in the cervical district, burdened by poor prognosis when diagnosed in an advanced stage. Immunotherapy with both anti-PD-1 nivolumab and pembrolizumab has the aim of increasing overall survival for patients with this malignancy. We report the first case of immune-related encephalitis caused by nivolumab in this setting of disease and present a brief review of the literature. A 60-year-old woman had been treated with concomitant chemoradiotherapy for a locally
Like
Comment
Share
